New Hydrophobic Acrylic Toric IOL Offers Predictable Astigmatism
Correction, Exceptional Rotational Stability
BRIDGEWATER, N.J., June 18, 2018 – Bausch + Lomb, a leading global eye health company, today announced that it has received Pre-Market Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the enVista® toric MX60T, the company’s first hydrophobic acrylic intraocular lens (IOL) for astigmatism correction.
The enVista® toric MX60T IOL features a one-piece aberration-free, aspheric optic with fenestrated, step-vaulted, modified C-loop haptic design that delivers exceptional rotational stability and ensures predictable astigmatism correction.1 Additionally, the optic’s posterior square edge provides a 360 degree barrier to posterior capsular opacification (PCO).2,3,4
The enVista® IOL material remains the only single-piece, hydrophobic acrylic material domestically available that have been proven to be glistening-free.1 The enVista® material also has the potential for increased resistance to scratches and abrasions that may occur during loading and surgical manipulation.5,6
“Building on the proven features and benefits of the enVista® family of IOLs, MX60T represents another innovation in the continued expansion of this lens platform,” said Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb. “The addition of this new lens to our portfolio offers surgeons a wide range of IOLs with seven cylinder powers to meet their astigmatic patients’ needs.”
In a recent prospective, multicenter study designed to evaluate the safety and effectiveness of the enVista® toric MX60T, the lens demonstrated 5° or less of absolute rotation in 100% of subjects.1
“The rotational stability of a toric IOL is critical, as even the slightest rotation can lead to a decrease in the toric effect, compromising outcomes,” said Mark Packer, medical monitor for the enVista® toric MX60T study and ophthalmologist, Boulder, CO. “The results of this study show that the enVista® toric MX60T lens provides excellent rotational stability, astigmatism correction and uncorrected visual acuity.1 I look forward to this lens being available to astigmatic cataract patients who would benefit from this technology based on the wonderful results I observed during the clinical study.”
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing, and restoring people’s eyesight. Our core businesses include ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. We develop, manufacture and market one of the most comprehensive product portfolios in our industry with products available in more than 100 countries.
®/tm are trademarks of Bausch & Lomb Incorporated or its affiliates.
© 2018 Bausch & Lomb Incorporated.
The website you are about to visit is not affiliated with Bausch + Lomb Incorporated. Bausch + Lomb is not responsible for the content, format, maintenance, or policies of the website you are about to enter and does not monitor non-affiliated websites for accuracy. Links to non-affiliated websites are provided as a convenience; they do not constitute an endorsement or support of any programs, products, or services associated with the website.